Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1780 in Chronic Kidney Disease
NCT07419828Phase 3
Key facts
- Status
- Recruiting
- Start
- Mar 2026
- Primary completion
- Apr 2030
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- HRS-1780
- Conditions
- chronic kidney disease (CKD)
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing HRS-1780 tablets with Placebo (2 arms). Primary endpoint: Time to the first appearance of the composite endpoint at 60 months. Started Mar 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
HRS-1780 tablets
Experimental arm receiving HRS-1780 oral tablets.
Placebo
Comparator arm receiving placebo oral tablets.
03
Who it enrols
Adults aged 18 to <80 years with chronic kidney disease (eGFR 25 to <90 mL/min/1.73m^2 and elevated UACR), serum potassium <=4.8 mmol/L, and HbA1c <10.5%. Excludes patients with severe uncontrolled hypertension, significant liver enzyme elevation, polycystic kidney disease, recent acute kidney injury, or recent severe cardiovascular events.
04
Endpoints
Primary
Time to the first appearance of the composite endpoint
Secondary
Annualized total slope of eGFR
Ratio of UACR to baseline
Proportion of participants whose UACR decreased by at least 30%
Beyond the preview
Go deeper on NCT07419828.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419828.